secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001193125-24-238572
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

HELIOS Phase 2: AMX0035 improves C-peptide AUC by +3.8 min*ng/mL at Week 24 in Wolfram syndrome
--------------------------------------------------------------------------------

- Primary endpoint: C-peptide AUC improved at Week 24 (ITT +3.8 min*ng/mL; Per Protocol +20.2) and sustained through Week 48 (+36.7).
- Glycemic control: HbA1c decreased (-0.09% at Week 24 to -0.35% at Week 36); time in target glucose range increased (+5.2% to +12.3%).
- All 12 participants showed stability/improvement on CGIC and PGIC; no serious AEs related to AMX0035; diarrhea most common.
- FDA and EU granted Orphan Drug Designation; company plans to meet FDA to discuss Phase 3, update in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524238572/0001193125-24-238572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524238572/d858945d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-238572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer